In this article, we will be taking a look at the 10 Most Promising Cancer Stocks According to Wall Street Analysts.
Regardless of the state of the economy, the pharmaceutical business has continued to be one of the healthcare market’s most robust sectors thanks to the consistent need for medications, vaccinations, and treatments for chronic illnesses. The S&P 500 Pharmaceutical Index has increased by more over 6%, surpassing the just over 1% increase of the overall S&P 500, demonstrating its defensive strength.
One of the healthcare fields that is growing the fastest, oncology, is a major factor in the long-term expansion of the industry. Immunotherapy and targeted therapeutic advancements, along with the rising global cancer incidence, continue to increase demand. Allied Market Research projects that the oncology pharmaceutical market will grow at a compound annual growth rate (CAGR) of 7.2% to reach $335.2 billion by 2032. Thanks to increased screening programs, increased treatment uptake, and long-term maintenance drugs, the US market for breast cancer medicines alone is projected to reach $6.6 billion by 2036 at a 5.6% CAGR.
The healthcare industry continues to profit from its defensive traits in spite of persistent macroeconomic uncertainties. Although investors are still sensitive to changes in Federal Reserve policy, geopolitical developments, and oil prices, Matt Powers of Powers Advisory Group called the market’s comeback to record highs within 15 trading days a “textbook” V-shaped recovery on April 17. A shift away from highly valued large-cap technology equities and toward more diversified portfolios has also been brought about by these worries. Oppenheimer’s John Stoltzfus says this change could help the healthcare industry, while JPMorgan analysts think the industry is stabilizing after a protracted period of underperformance, even if it has lost roughly 4% this year.
At the same time, rising merger and acquisition activity and stronger insider buying are reinforcing confidence in the industry’s outlook. Deloitte’s February 16, 2026, Global Health Care Outlook found that more than 70% of non-US healthcare executives expect higher revenues and profits, highlighting growing optimism for the sector’s long-term growth prospects.
With that said, let’s now take a look at the most promising stocks.
Our Methodology
For our methodology, we screened for cancer stocks with an analyst upside of at least 20%. From this list, we selected the 10 stocks with the most recent news and developments and ranked them in ascending order based on their analyst upside as of June 25.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).
Here is our list of the 10 most promising cancer stocks according to Wall Street analysts.
10. Caris Life Sciences, Inc. (NASDAQ:CAI)
Price Target Upside: 49.73%
Caris Life Sciences, Inc. (NASDAQ:CAI) is one of the most promising stocks on our list.
TheFly reported on June 1 that Wolfe Research analyst Mike Polark initiated coverage of CAI and lowered the stock’s rating to Peer Perform from Outperform. The analyst began coverage without assigning a price target.
In other news, on June 16, Caris Life Sciences, Inc. (NASDAQ:CAI) announced that its common shares would receive a dual listing on NYSE Texas, effective June 17, 2026. The company will continue trading on Nasdaq while gaining an additional listing under the same CAI ticker, expanding visibility among investors in Texas and across the broader U.S. market. CAI stated that the move reflects its continued development as a public company and highlights its strong connection to Texas, where it maintains its headquarters and employs more than 450 team members. The company emphasized that the listing supports its focus on advancing AI-driven precision medicine and improving patient outcomes through innovative healthcare solutions.
Caris Life Sciences, Inc. (NASDAQ:CAI) is a TechBio and precision medicine company using molecular profiling and AI to advance personalized oncology and chronic disease care.
9. BeOne Medicines AG (NASDAQ:ONC)
Price Target Upside: 50.00%
BeOne Medicines AG (NASDAQ:ONC) is one of the most promising stocks on our list.
TheFly reported on June 2 that RBC Capital analyst Leonid Timashev increased the firm’s price target on ONC to $436 from $425 while maintaining an Outperform rating on the shares. The update followed the company’s ASCO presentations featuring three oncology programs, including a CDK4 inhibitor for breast cancer, a GPC3-41BB bispecific candidate for hepatocellular carcinoma, and a B7-H4 antibody-drug conjugate for ovarian cancer. RBC Capital noted that these assets demonstrated encouraging potential, with differentiated safety or efficacy profiles that could position them as leading therapies or strong competitors in their respective markets over time.
More recently, on June 11, BeOne Medicines AG (NASDAQ:ONC) presented Phase 3 data from the SEQUOIA trial in patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). The analysis, including nearly 6.5 years of follow-up, showed sustained clinical benefits with Brukinsa, highlighting its continued role as a leading BTK inhibitor option. Data from older patients aged 80 and above demonstrated that advanced age did not reduce treatment benefits. The findings further supported Brukinsa’s strong efficacy and safety profile, reinforcing its potential position as a foundational therapy in CLL. The dataset will be presented at the 2026 European Hematology Association Congress.
BeOne Medicines AG (NASDAQ:ONC) is a global oncology company developing and commercializing innovative targeted therapies and immuno-oncology treatments to improve access to cancer care worldwide.
8. Zai Lab Limited (NASDAQ:ZLAB)
Price Target Upside: 67.06%
Zai Lab Limited (NASDAQ:ZLAB) is one of the most promising stocks on our list.
TheFly reported on June 16 that ZLAB announced that the European Medicines Agency (EMA) granted Orphan Drug Designation (ODD) to zocilurtatug pelitecan (zoci, formerly ZL-1310), the company’s potential first-in-class DLL3-targeting antibody-drug conjugate (ADC) for pulmonary neuroendocrine carcinomas (NECs). The designation followed a positive recommendation from the EMA’s Committee for Orphan Medicinal Products, recognizing the significant unmet need for new treatment options in this disease area. The decision was supported by early clinical findings in relapsed or refractory extensive-stage small cell lung cancer, suggesting zoci may provide durable responses and potential advantages compared with existing therapies. The designation may also provide regulatory benefits, including development incentives and possible market exclusivity.
Earlier on June 8, Zai Lab Limited (NASDAQ:ZLAB) announced that China’s National Medical Products Administration (NMPA) approved the Biologics License Application (BLA) for TIVDAK (tisotumab vedotin for injection) for adults with recurrent or metastatic cervical cancer following disease progression after chemotherapy. The approval was supported by results from the global Phase 3 innovaTV 301 trial, which demonstrated an overall survival benefit compared with chemotherapy. Data from the Chinese patient subgroup showed consistent clinical benefit, including a 45% reduction in the risk of death compared with chemotherapy. No new safety concerns were identified, supporting TIVDAK’s potential use in China.
Zai Lab Limited (NASDAQ:ZLAB) is a global biopharmaceutical company developing and commercializing innovative therapies in oncology, immunology, neuroscience, and infectious diseases across major global markets.
7. Tyra Biosciences, Inc. (NASDAQ:TYRA)
Price Target Upside: 71.30%
Tyra Biosciences, Inc. (NASDAQ:TYRA) is one of the most promising stocks on our list.
TheFly reported on June 17 that Oppenheimer initiated coverage of TYRA with an Outperform rating and a $50 price target. The firm highlighted TYRA’s upcoming clinical milestones, particularly the expected three-month complete response data from the SURF302 study in induction-refractory non-muscle invasive bladder cancer, anticipated in August 2026. Following discussions with company management, Oppenheimer expressed increased confidence in TYRA’s outlook. The firm also noted the company’s strong cash position of $383.5 million, expected to support operations into the second half of 2028, while viewing its oral treatment approach as a potential advantage in a disease area marked by repeated procedures and recurrence challenges.
Earlier on May 13, Tyra Biosciences, Inc. (NASDAQ:TYRA) released its first quarter 2026 financial results, reporting increased investment in clinical development programs. Research and development expenses reached $33.5 million for the quarter ended March 31, 2026, compared with $25.0 million in the prior-year period, mainly due to ongoing dabogratinib activities, including the BEACH301 and SURF302 trials and preparations for SURF303. General and administrative expenses rose to $8.5 million from $6.9 million, driven by higher personnel-related costs. The company reported a first-quarter net loss of $39.3 million, compared with a net loss of $28.1 million during the same period in 2025.
Tyra Biosciences, Inc. (NASDAQ:TYRA) is a clinical-stage biotechnology company developing precision medicines targeting FGFR biology to treat cancer and genetically defined diseases.
6. Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)
Price Target Upside: 86.77%
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is one of the most promising stocks on our list.
TheFly reported on June 12 that Guggenheim analyst Brad Canino reduced the price target for SNDX to $31 from $34 while maintaining a Buy rating on the shares. The updated outlook reflected revisions to the firm’s acute myeloid leukemia market assumptions following new insights on revumenib’s post-transplant maintenance duration from recent medical conference updates. The analyst also considered recent commercial updates from Syndax and Kura Oncology when adjusting the valuation.
Moreover, on June 11, Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) announced the publication of clinical results from the Phase 1/2 SAVE trial evaluating an oral combination regimen of Revuforj (revumenib), decitabine/cedazuridine, and venetoclax in patients with relapsed or refractory acute myeloid leukemia with NPM1 mutations, KMT2A rearrangements, or NUP98 rearrangements. The data were published in the Journal of Clinical Oncology and presented at the 2026 European Hematology Association Congress. The study enrolled 42 patients, including adolescents, and showed an overall response rate of 88% with a 71% composite complete remission rate. The regimen demonstrated activity across genetic subgroups, including patients previously treated with venetoclax, while maintaining a generally manageable safety profile.
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is a commercial-stage biopharmaceutical company developing innovative therapies for cancer and immune-mediated diseases, with a focus on hematologic malignancies.
While we acknowledge the potential of SNDX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SNDX and that has 100x upside potential, check out our report about the cheapest AI stock.
Click to continue reading and see the 5 Most Promising Cancer Stocks According to Wall Street Analysts.
Disclosure: None. None. Follow Insider Monkey on Google News.
